top of page
  • Active, Not enrolling

NCT02658929: Phase 1 - Study of bb2121 in BCMA-Expressing refractory Multiple Myeloma CRB-401

Updated: Sep 27, 2022

CRB-401

NCT02658929: Phase 1: Study of bb2121 in Multiple Myeloma

bb2121

NCT02658929: Phase 1: Study of bb2121 in Multiple Myeloma


Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM). Experimental: bb2121 - bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy.


This is a 2-part, non-randomized, open label, multi-site Phase 1 study. the study design consists of 2 parts: Part A (Dose Escalation), in which the RP2D is determined, and Part B (Expansion Cohorts), in which subjects are treated with the determined RP2D.


Sponsor


Collaborator

 

ClinicalTrials.gov Identifier: NCT02658929

Official Title: CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

First Posted: January 20, 2016


Click here for details on ClinicalTrials.gov

 
 

N Engl J Med : May 2nd, 2019

PMID: 31042825

 

CAR T-Cell Therapy in Multiple Myeloma Yields 100% Response Rate

Asco Post July, 2017



First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.

Meeting Abstract, ASCO 2017

 

- California: Stanford Cancer Center

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- Massachusetts: Massachusetts General Hospital Boston

- Minnesota: Mayo Clinic Rochester Minnesota

- New Jersey: Hackensack University Medical Center

- New York: Tisch Cancer Institute Mount Sinai Hospital New York

- Tennessee: Sarah Cannon Research Institute Nashville

 

Locations

United States, California

United States, Maryland

United States, Massachusetts

United States, Minnesota

United States, New Jersey

United States, New York

United States, Tennessee




Comments


Posts Archive
bottom of page